SGEN

Seattle Genetics, Inc. Press Releases

$46.58
*  
1.29
2.69%
Get SGEN Alerts
*Delayed - data as of Aug. 3, 2015  -  Find a broker to begin trading SGEN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SGEN After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Seattle Genetics Reports Second Quarter 2015 Financial Results
7/30/2015 4:02:00 PM - Business Wire
▼-1.61 % Price Change since this news event. The Volume Ratio is 1.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus Erythematosus, a Chronic Autoimmune Disease
7/9/2015 9:00:00 AM - Business Wire
▲1.09 % Price Change since this news event. The Volume Ratio is 0.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial Results on July 30, 2015
7/8/2015 9:00:00 AM - Business Wire
▲0.22 % Price Change since this news event. The Volume Ratio is 1.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma
6/17/2015 9:00:00 AM - Business Wire
▲1.17 % Price Change since this news event. The Volume Ratio is 1.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Unum Therapeutics Announces $65 Million Series B Financing Round
6/11/2015 8:00:00 AM - Business Wire
▲0.28 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration
6/8/2015 9:00:00 AM - Business Wire
▼-0.62 % Price Change since this news event. The Volume Ratio is 1.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in the AETHERA Post-Transplant Consolidation Setting and in Frontline DLBCL at ASCO Annual Meeting
6/1/2015 10:45:00 AM - Business Wire
▲9.09 % Price Change since this news event. The Volume Ratio is 0.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting
5/28/2015 9:00:00 AM - Business Wire
▲9.60 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day